Common Stock, $0.01 par value
- Symbol
- VRDN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Viridian Therapeutics, Inc.
VRDNNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 2, 2026, Viridian Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of the Company’s common stock as of the close of business on April 7, 2026 (the “Record Date”) were entitled to vote.…
Company context
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Current securities
Recent company filings
- SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding Viridian Therapeutics, Inc.\DEAug 20, 2026
- 144 filingAug 19, 2026
- SCHEDULE 13G/A - filed by Kynam Capital Management, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
- SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
- 10-Q filingAug 6, 2026
Registered securities in this filing
Viridian Therapeutics, Inc.\DE · 8-K · Filed 2026-06-03
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 2, 2026, Viridian Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of the Company’s common stock as of the close of business on April 7, 2026 (the “Record Date”) were entitled to vote. As of the close of business on the Record Date, 103,071,889 shares of the Company’s common stock were issued and outstanding.
At the Annual Meeting, each of the Company’s director nominees was elected and the other proposals voted on were approved. The final voting results are set forth below:
1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders:
For Withheld Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Tomas Kiselak 72,363,500 14,475,646 6,733,104
Jennifer K. Moses 86,378,842 460,304 6,733,104
2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
For Against Abstentions Broker Non-Votes
──────────────────────────────────────────────────────────────────
92,866,008 512,582 193,660 —
3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers:
For Against Abstentions Broker Non-Votes
────────────────────────────────────────────────────────────────────
83,512,086 3,113,724 213,336 6,733,104
4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers:
1 Year 2 Years 3 Years Abstain
─────────────────────────────────────────────────────
86,084,347 29,762 517,682 207,355
As a result of the foregoing vote, the Company’s Board of Directors has determined that the Company will conduct a non-binding advisory vote on the compensation of the Company’s named executive officers every year.